CAN2: A NEW METHOD FOR EXPRESSING SURVIVAL AND LIFE EXPECTANCY IN CANCER PATIENTS  by Messori, A & Trippoli, S
 6
 
Abstracts
 
product, presenting it objectively, without exaggeration
and without being misleading. EFPIA and IFPMA also
publish Codes of Practice for the Promotion of Medi-
cines. In these approaches HE data are not explicitly con-
sidered; the focus is clinical. Similarly, until recently, leg-
islation for the separate review of HE data did not exist
in the US. In addition, a recent cross-functional initiative
through ISPOR to develop guidelines for healthcare eco-
nomic promotional materials has now been reported.
CONCLUSION: We have identified no specific guide-
lines for advertising using HE data in the EU. Given this,
key questions are: 1) Do existing codes of practice offer
enough scope to review HE data? and 2) How can we en-
sure quality assurance of HE information provided to de-
cision-makers?
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HOW DO PATIENTS MAKE SATISFACTION 
JUDGMENTS? ANSWERS FROM STRUCTURAL 
EQUATION MODELING
Trudeau E
MAPI Values, Lyon, France
Quality of life and patient satisfaction cohabit more and
more in the same paradigm, through the notion that pa-
tient satisfaction with care and treatment can lead to pos-
itive outcomes, which in turn adds to overall clinical ef-
fectiveness. Yet patient satisfaction is often used without
a clear understanding of the concept.
OBJECTIVE: To test a model of patient satisfaction that
would identify the antecedents of the satisfaction judgment.
METHOD: Self-administered questionnaire to 532 inpa-
tients of two acute-care hospitals in Montreal (Canada).
The questionnaire consisted of six Likert scales measur-
ing: expectations (3 items), perceived quality (17 items),
conformity to expectations (3 items), needs (6 items),
fairness (2 items), and satisfaction (10 items). Scales reli-
ability and construct validity were assessed with Cron-
bach alpha coefficient of internal consistency and confir-
matory factorial analysis. The model was tested with
causal modeling (LISREL 8).
RESULTS: All alpha coefficients ranged from 0.70 to
0.91. The model provides satisfactory fit to the data (
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26.44, df 
 

 
 28, p 
 

 
 0.55) and explains 61% of the varia-
tion in satisfaction. Examination of total effects (sum of di-
rect and indirect effects of one variable on another) reveals
that perceived quality has the greatest influence on satis-
faction (total effect 0.62), followed by conformity to ex-
pectation (total effect 0.44), fairness (total effect 0.44),
needs (total effect 0.16), and expectations (total effect
0.11). In conclusion, the utilization of satisfaction informa-
tion to its full potential not only requires reliable and valid
instruments, but also relevant concepts, such as perceived
quality and conformity to expectations, to take into ac-
count the complexity of the satisfaction judgment.
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COST-EFFECTIVENESS ANALYSIS OF
HIGH-DOSE CHEMOTHERAPY WITH 
HEMATOPOIETIC RESCUE AS PRIMARY 
TREATMENT FOR METASTATIC
BREAST CANCER
Trippoli S, Messori A
Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione 
Farmaci, Azienda Ospedaliera Careggi, Florence, Italy
OBJECTIVES: The analysis of published survival curves
can be used as the basis for conducting cost-effectiveness
analyses in which two treatments are compared in terms
of cost per life year saved. In patients with metastatic
breast cancer, high-dose chemotherapy (HDC) with au-
tologous bone marrow transplantation (ABMT) has been
reported to improve survival in comparison with control
patients who receive standard chemotherapy.
METHODS: An incremental cost-effectiveness analysis
was undertaken in which the Gompertz model was used
to determine a lifetime estimate of patient-years gained
by subjects given HDC with hematopoietic rescue in
comparison with controls. Our study utilized the clinical
data reported in a published clinical trial. This random-
ized clinical trial involved 45 patients subjected to HDC
with ABMT and 45 controls given chemotherapy.
RESULTS: Lifetime survival advantage for patients in the
HDC with ABMT group was estimated as 72.5 discounted
patient-years for every 100 patients. The use of HDC with
ABMT, as opposed to standard chemotherapy alone, was
associated with an incremental cost of about $55,000 per
discounted life year gained.
CONCLUSIONS: The cost-effectiveness ratio of high-
dose chemotherapy combined with autologous bone mar-
row transplantation in patients with metastatic breast can-
cer is borderline if one considers that acceptable figures of
cost per life year gained are generally below $50,000.
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We describe a new method for expressing survival in can-
cer. Our method has the following characteristics: In ana-
lyzing a survival curve (first analysis), the plateau of the
right portion of the curve is extrapolated to infinity by as-
signing a normal life expectancy to long-term survivors
(“cured” patients). A second survival curve (second anal-
ysis), which represents the expected survival of a healthy
patient cohort (age-matched and gender-matched with
the patient cohort under study), is constructed. The sec-
ond curve is used as a reference for internal compari-
sons. Both curves are assessed by measuring the area un-
der the curve (AUC). The ratio of the AUC from the first
analysis to the AUC from the second analysis quantifies
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the impact of the disease on life expectancy. As an exam-
ple of the application of our method, we have reanalyzed
a survival data set reported by Spinolo et al. (1992) that
refers to patients with acute leukemia who relapsed after
their first allogeneic bone marrow transplant (BMT). We
obtained the following results: total AUC leukemia pa-
tients (normalized to 100 patients)  10,590 months,
mean lifetime survival per patient (MLS)  105.9 months
or 8.8 years; total AUC healthy subjects  58,376
months, MLS  583.8 months or 48.6 years. These data
indicate that the average life expectancy (or MLS) after a
second BMT was 8.8 years compared with 48.6 years in
an age-matched and gender-matched cohort of healthy
subjects. Our survival analysis shows that, in this very se-
rious disease condition, the absolute reduction in life ex-
pectancy was 39.8 years per patient and the percent re-
duction was 82%.
 
CAN3
 
PRACTICE PATTERNS OF CHEMOTHERAPY 
USAGE AND ASSOCIATED NEUTROPENIA AND 
FEBRILE NEUTROPENIA (FN) IN EUROPE
Lyman GH
London School of Hygiene and Tropical Medicine, London, UK; 
H. Lee Moffitt Cancer Center and Research Institute at the 
University of South Florida, Tampa, FL, US
Neutropenia and associated FN are major dose-limiting
toxicities of cancer chemotherapy and impact consider-
ably on the costs of care and patient quality of life. There
is little information available concerning patterns of che-
motherapy treatment and their associated complications
in Europe.
OBJECTIVES: To study patterns of chemotherapy usage
and the occurrence of neutropenia and FN in cancer pa-
tients in Europe.
METHODS: Recent patterns of cancer treatment were
examined from survey data provided by ISIS Research
for the five major European economic markets ($bn
GDP): Germany (2115), France (1394), United Kingdom
(1278), Italy (1146), and Spain (533). Data were evalu-
ated from 60 cancer specialists and 1200 cancer patients
receiving cancer treatment in each country. Practice pat-
terns examined included the use of systemic chemother-
apy, the occurrence of neutropenia and FN and the type
of supportive care provided.
RESULTS: Ninety percent of patients were receiving
treatment with chemotherapy, of which 20% was admin-
istered in an adjuvant fashion. Average patient age was
55 years and 53% were female. Major treated cancers in-
cluded those of breast (23%), colon (13%), and lung
(12%). Approximately one-half of patients were newly
diagnosed, while 25% were described as heavily pre-
tested. Nearly 40% of patients had experienced a prior
episode of severe neutropenia and 10% had experienced
a previous infection. Concurrent use of colony-stimulat-
ing factors (CSFs) was reported in 15% of patients. Ma-
jor factors predicting CSF use included previous or antici-
pated severe neutropenia, FN, or infection. Considerable
regional variation was evident in the treatment practices
observed.
CONCLUSIONS: Neutropenia and FN are frequent com-
plications of systemic cancer chemotherapy in Europe.
ECONOMIC AND OUTCOMES STUDY RESULTS 
FOR NEUROLOGIC AND GASTRIC DISORDERS
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AN 11-YEAR, CONTROLLED STUDY OF 
HEALTHCARE RESOURCE USE AND 
MORTALITY FOR PATIENTS WITH 
PARKINSON’S DISEASE
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There are few long-term data about Parkinson’s disease
(PD) other than from hospital clinics, which may see a bi-
ased selection of patients.
 
METHODS:
 
 We used two populations in Tayside: one
with complete prescribing data from 1989–1995 (n 
30,000) and the second with data from 1985–1995 (n 
10,000). The first 6 months of data were used to identify
incident cases and to exclude those who had previously
taken a neuroleptic drug. Cases were matched for age,
sex, and general practice to nine controls.
RESULTS: The number of cases of incident PD was 108
in the 7-year cohort and 28 in the 11-year cohort. In the
7-year cohort, patients were aged 45–95 (median 76.0),
and 55% were male. The most commonly prescribed
drug was co-beneldopa at a mean dose of 187 mg. In
comparison with control, PD patients were significantly
more likely to receive additional drugs for gastrointesti-
nal (relative risk [RR] 2.0; 95% confidence interval [CI]
1.4–3.3) and cardiovascular (RR 1.7; CI 1.2–2.4) disor-
ders. Median costs of hospitalization were higher in PD
(14,119 vs. 5,077; p  0.0001) because of increased
numbers of episodes per patient and costs per episode
(1,965 vs. 1,526; p  0.002). Relative risk of mortality in
PD patients was very similar in the 7-year cohort (RR 
2.50, CI 1.74–3.57) and the 11-year cohort (RR  2.25,
CI 1.43–3.54).
CONCLUSIONS: This population-based study provides
an unbiased estimate of the costs and mortality of PD,
hence of the potential value of improved treatment.
